Euro vs US Dollar

Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.

Registrieren

ALXO ALX Oncology Holdings Inc

14,21

-0,45 (-3,07%)

17 Mai 2024 - Geschlossen

Verzögert um 15 Minuten

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Article too big to display. Click here to view on the SEC website

ALX Oncology (NASDAQ:ALXO)
Historical Stock Chart
Von Apr 2024 bis Mai 2024

Click Here for more ALX Oncology Charts.

ALX Oncology (NASDAQ:ALXO)
Historical Stock Chart
Von Mai 2023 bis Mai 2024

Click Here for more ALX Oncology Charts.

News ALX Oncology Holdings Inc

Form 4 - Statement of changes in beneficial ownership of securities
Mittwoch 15 Mai 2024 (2 Tage vor) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Montag 13 Mai 2024 (4 Tage vor) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Donnerstag 9 Mai 2024 (1 Woche vor) • Edgar (US Regulatory)

ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
Donnerstag 9 Mai 2024 (1 Woche vor) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Mittwoch 8 Mai 2024 (1 Woche vor) • Edgar (US Regulatory)

ALX Oncology Appoints Allison Dillon as Chief Business Officer
Dienstag 7 Mai 2024 (1 Woche vor) • GlobeNewswire Inc.

Form 144 - Report of proposed sale of securities
Montag 6 Mai 2024 (2 Wochen vor) • Edgar (US Regulatory)

ALX Oncology Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal Cancer
Dienstag 30 April 2024 (2 Wochen vor) • GlobeNewswire Inc.

ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting
Mittwoch 24 April 2024 (3 Wochen vor) • GlobeNewswire Inc.

ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)
Dienstag 9 April 2024 (1 Monat vor) • GlobeNewswire Inc.

Form 8-K - Current report
Donnerstag 7 März 2024 (2 Monate vor) • Edgar (US Regulatory)

ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Donnerstag 7 März 2024 (2 Monate vor) • GlobeNewswire Inc.

Weitere ALX Oncology Holdings Inc News-Artikel

FTP Innovative Technolog...

BNP Paribas Issuance

Societe Generale Effekten

Aegon Levensverzekering ...

Viatar CTC Solutions (GM)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen